Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy.

Asian journal of psychiatry - 1 Dec 2020

Chen Jianmin, Lu Weihong, Zhang Yi, Fan Weixing, Tang Wei, Zhang Chen

Abstract excerpt

In this study, we hypothesized that fatty acid desaturase-1 (FADS1) and fatty acid desaturase-2 (FADS2) may mediate metabolic syndrome (MetS) in patients receiving olanzapine monotherapy. 216 schizophrenia patients were recruited. There is a significant difference between the patients with or without MetS in term of the expression of FADS1 mRNA (F = 4.58, P = 0.03), but not FADS2 mRNA (F = 1.29, P = 0.26). We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Delta-5 Fatty Acid Desaturase
Share to Fatty Acid Desaturases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Metabolic Syndrome

Share to Olanzapine

Share to Polymorphism, Single Nucleotide

Share to Schizophrenia

Source

Identifiers

PMID: 32801079
DOI: 10.1016/j.ajp.2020.102352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy.PMID 32801079Read ↗

Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia.Semantic proximity Read ↗

A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia.Semantic proximity Read ↗

Prevalence and factors associated of metabolic syndrome in first- treatment drug-naïve schizophrenia patients: a large-scale cross- sectional studySemantic proximity Read ↗

The Multidimensional Nature of Metabolic Syndrome in Schizophrenia: Lessons from Studies of One-Carbon Metabolism and DNA MethylationSemantic proximity Read ↗

Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.Semantic proximity Read ↗

Functional Impact of the FADS1 rs174546 Single Nucleotide Polymorphism on Serum Lipid Levels: Insights from Molecular Mechanisms and Therapeutic Perspectives in Korean Population.Semantic proximity Read ↗

Gender differences in prevalence and associated factors of metabolic syndrome in first-treatment and drug-naïve schizophrenia patientsSemantic proximity Read ↗

NOS1AP Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with SchizophreniaSemantic proximity Read ↗

From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids MetabolismSemantic proximity Read ↗

Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis.Semantic proximity Read ↗

Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.Semantic proximity Read ↗

Fatty acid desaturase 2 (FADS 2) rs174575 (C/G) polymorphism, circulating lipid levels and susceptibility to type-2 diabetes mellitus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.